McKesson Expands Oncology Distribution Network with LYMPHIR and PHYRAGO Partnerships
Key Insights
McKesson Corporation has secured distribution agreements for two novel oncology therapies, LYMPHIR and PHYRAGO (search), reinforcing its position in the specialty pharmaceutical market.
LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma (search) developed by Citius Oncology (search), will be distributed nationwide through McKesson's network.
PHYRAGO (search), Cycle Pharmaceuticals' first oncology product launched in partnership with Handa Therapeutics (search), is exclusively available through Onco360 (search) with McKesson providing distribution support.
McKesson Corporation has strengthened its position in the specialty pharmaceutical distribution market through two significant oncology partnerships, securing distribution rights for innovative cancer (search) therapies that expand patient access to cutting-edge treatments.
LYMPHIR Distribution Agreement
Citius Oncology (search) recently announced its partnership with McKesson Corporation to distribute LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma (search), nationwide through McKesson's extensive distribution network. This agreement establishes McKesson as one of the primary authorized distributors for LYMPHIR, significantly expanding patient access to this novel oncology treatment across the United States.
The partnership represents McKesson's growing integration in high-growth therapeutic areas and demonstrates its critical role in making complex therapies broadly accessible to patients requiring specialized cancer (search) treatments.
PHYRAGO Launch Partnership
Earlier this month, Cycle Pharmaceuticals announced the US launch of PHYRAGO (search), its first oncology product, developed in partnership with Handa Therapeutics (search). The therapy is exclusively available through Onco360 (search), with distribution support provided by McKesson alongside Cencora and Cardinal Health.
This collaboration highlights McKesson's ongoing role in the specialty pharmaceutical supply chain, particularly in oncology, through exclusive access to newly launched therapies. The partnership reinforces the company's position within the specialty market and its ability to support complex product launches.
Strategic Market Position
These distribution agreements align with McKesson's broader strategic initiatives in oncology. The company launched the Precision Care Companion initiative in April, aimed at advancing cancer (search) treatment through technology and operational best practices. This initiative reflects McKesson's efforts to solidify its foothold in oncology distribution and related services.
The partnerships support McKesson's investment narrative, which relies on sustained growth from rising demand for specialty and oncology pharmaceuticals, backed by the company's scale and critical supply chain role. McKesson's involvement in distributing these innovative therapies reinforces its position within the specialty market while demonstrating its capacity to support emerging treatment categories.
Financial Outlook
McKesson's outlook anticipates $478.8 billion in revenue and $5.3 billion in earnings by 2028, based on an expected 8.2% annual revenue growth rate and a $2.1 billion increase in earnings from the current $3.2 billion. The specialty pharmaceutical distribution agreements contribute to this growth trajectory by positioning the company in high-value therapeutic areas.
Simply Wall St Community members estimate McKesson's fair value ranging from $625 to $1,365 per share, reflecting varied perspectives on the company's growth potential in specialty pharmaceuticals versus potential regulatory pressures on drug pricing that could impact profit margins.